Date: 16-Aug-2019

SMC rejects Orkambi, accepts four medicines

The committee, which advises on newly licensed medicines for use by NHSScotland, firstly accepted Akceaís Tegsedi for the treatment of polyneuropathy (a form of nerve damage) in adults with hereditary transthyretin amyloidosis (hATTR).